title: Quantitative analysis of low-dose aspirin-associated small bowel injury using a capsule endoscopy scoring index.
abstract: OBJECTIVE
  The major limitation of capsule endoscopy (CE) has been the lack of a standardized and validated severity scale for mucosal injury. The aim of the present study was to verify the usefulness of quantifying small bowel mucosal changes associated with giving low-dose aspirin (LDA) using a CE scoring index.
  
  
  METHODS
  The CE score for small bowel mucosal injury was investigated to evaluate the severity of mucosal injury. Healthy volunteers and patients suspected of having small bowel disease were recruited for this study. The short-term LDA group (V+S-LDA group) consisted of volunteers who took low-dose aspirin for 14days; this group was then compared with healthy volunteers who did not receive LDA treatment (V-Control group). The long-term LDA group (L-LDA group) consisted of patients with at least a 3-month history of daily LDA use; this group was compared with non-users of LDA (P-Control group).
  
  
  RESULTS
  The CE score was significantly higher in the V+S-LDA group than in the V-Control group. In the V-Control group, almost all the subjects were categorized as exhibiting a 'normal' change. 'Mild' changes were observed significantly more frequently in the V + S-LDA group than in the V-Control group. The CE score was significantly higher in the L-LDA group than in the P-Control group. 'Mild' or 'moderate or severe' changes were observed significantly more frequently in the L-LDA group than in the P-Control group.
  
  
  CONCLUSIONS
  The CE scoring system was useful for evaluating LDA-associated small bowel mucosal disease activity and for objectively scoring the small bowel inflammatory disease state.
authors.affiliation: Division of Gastroenterology, Yokohama City University School of Medicine, Japan. endo1978@yokohama-cu.ac.jp
authors.forename: Hiroki
authors.initials: H
authors.lastname: Endo
authors.forename: Kunihiro
authors.initials: K
authors.lastname: Hosono
authors.forename: Takuma
authors.initials: T
authors.lastname: Higurashi
authors.forename: Eiji
authors.initials: E
authors.lastname: Sakai
authors.forename: Hiroshi
authors.initials: H
authors.lastname: Iida
authors.forename: Yasunari
authors.initials: Y
authors.lastname: Sakamoto
authors.forename: Koji
authors.initials: K
authors.lastname: Fujita
authors.forename: Hirokazu
authors.initials: H
authors.lastname: Takahashi
authors.forename: Tomoko
authors.initials: T
authors.lastname: Koide
authors.forename: Masato
authors.initials: M
authors.lastname: Yoneda
authors.forename: Chikako
authors.initials: C
authors.lastname: Tokoro
authors.forename: Masahiko
authors.initials: M
authors.lastname: Inamori
authors.forename: Yasunobu
authors.initials: Y
authors.lastname: Abe
authors.forename: Nobuyuki
authors.initials: N
authors.lastname: Matsuhashi
authors.forename: Atsushi
authors.initials: A
authors.lastname: Nakajima
mesh_terms: D000328:Adult; D001241:Aspirin / Q000008:administration & dosage*; D053704:Capsule Endoscopy; D004751:Enteritis / Q000175:diagnosis*; D005260:Female; D006801:Humans; D007421:Intestine, Small / Q000187:drug effects*; D008297:Male; D010975:Platelet Aggregation Inhibitors / Q000008:administration & dosage*; D012189:Retrospective Studies; D012720:Severity of Illness Index
chemical_list: D010975:Platelet Aggregation Inhibitors; D001241:Aspirin